Physician profile
Duc H DO
NPI 1336136951
$13,690.97
in general payments reported to CMS, 2019-2025
37 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,488 · 2020: $1,641 · 2021: $1,808 · 2022: $1,680 · 2023: $2,001 · 2024: $2,390 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,155 · Travel and Lodging: $868 · Education: $50.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,154.68 |
| Travel and Lodging | $868.08 |
| Education | $50.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,207.87 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Abbott Laboratories | $1,949.68 | 2019-2025 | Aveir, Freestyle Libre 3 |
| Novo Nordisk INC | $1,531.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,308.53 | 2019-2025 | Tepezza, Evenity, Prolia |
| Astrazeneca Pharmaceuticals Lp | $807.51 | 2019-2023 | Farxiga |
| Abbvie INC. | $801.28 | 2019-2025 | Synthroid, Ubrelvy |
| Dexcom, INC. | $755.66 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $622.68 | 2019-2023 | |
| Insulet Corporation | $519.12 | 2019-2025 | Omnipod, Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.44 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Mannkind Corporation | $475.32 | 2019-2025 | Afrezza |
| Ibsa Pharma INC. | $329.25 | 2019-2023 | Tirosint, Licart |
| Merck Sharp & Dohme LLC | $223.18 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Currax Pharmaceuticals LLC | $158.39 | 2019-2023 | Contrave, Nexlizet, Nexletol |
| Endo Pharmaceuticals INC. | $150.13 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $141.55 | 2019-2020 | |
| Leo Pharma INC. | $135.62 | 2023 | Adbry |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Cequr Corporation | $120.79 | 2022-2024 | Cequr Simplicity |
| Amarin Pharma, INC. | $116.27 | 2019-2020 | |
| Medtronic, INC. | $98.88 | 2022-2025 | Azure Xt Dr Mri Surescan, Minimed 780g, Pulseselect |
| Antares Pharma, INC. | $76.22 | 2019-2022 | |
| Acella Pharmaceuticals, LLC | $72.55 | 2023-2025 | NP Thyroid 60 |
| Esperion Therapeutics, INC. | $60.97 | 2021 | |
| Shield Therapeutics INC | $56.47 | 2022 | |
| Becton, Dickinson and Company | $56.34 | 2019-2022 | |
| Vivus LLC | $50.60 | 2019-2020 | |
| Sequel Med Tech, LLC | $37.21 | 2025 | Twiist |
| Embecta Corp. | $36.00 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Tolmar, INC. | $29.31 | 2025 | Jatenzo |
| Medtronic Minimed, INC. | $28.44 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.28 | 2025 | Gvoke Hypopen |
| Zealand Pharma US, INC. | $18.82 | 2021 | |
| Valeritas, INC. | $17.66 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $15.59 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.14 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duc DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.